The company previously forecast FY24 revenue of $88M-$92M and adjusted EBITDA $8M-$10M. The current revenue consensus for FY24 is $89.5M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEO
- OptimizeRx initiated with an Equal Weight at Stephens
- OptimizeRx lowered to $16 at Roth MKM as revenues miss
- OptimizeRx price target lowered to $7 from $14 at RBC Capital
- OptimizeRx price target lowered to $8 from $13 at Stifel